Difference between revisions of "Levoleucovorin (Fusilev)"

Revision as of 20:53, 5 May 2023

General information

Class/mechanism: Folic acid analog that is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid (racemic d,l Folinic acid (Leucovorin)). Counteracts the effects of folic acid antagonists such as methotrexate, which acts by inhibiting dihydrofolate reductase. Enhances the activity of Fluorouracil (5-FU) by inhibiting thymidylate synthase.^[1]^[2]^[3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Note: these are diseases where folinic acid is used as an adjuvant to Fluorouracil (5-FU), as opposed to an antidote as it is used in conjunction with Methotrexate (MTX)

Cervical cancer ‎
Cholangiocarcinoma
Colorectal cancer
- Colon cancer
- Rectal cancer
Esophageal cancer ‎
- Esophageal adenocarcinoma
Gastric cancer ‎
Hepatocellular carcinoma ‎
Pancreatic cancer ‎ ‎

Patient drug information

History of changes in FDA indication

2008-03-07: FDA approved "to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists." "Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma."

Also known as

Generic name: levoleucovorin calcium
Brand name: Fusilev

References

‎ ‎

[insert-1] 1.0 ^1.1 ^1.2 Levoleucovorin (Fusilev) package insert

[2] Levoleucovorin (Fusilev) package insert (locally hosted backup)

[3] Fusilev manufacturer's website

[4] Levoleucovorin (Fusilev) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 25: / Line 25: @@
 ==History of changes in FDA indication==
-*3/7/2008: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020140lbl.pdf FDA approved] "to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists." "Levoleucovorin rescue is indicated after high-dose methotrexate therapy in [[Bone sarcoma | osteosarcoma]]."
+*2008-03-07: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020140lbl.pdf FDA approved] "to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists." "Levoleucovorin rescue is indicated after high-dose methotrexate therapy in [[Bone sarcoma | osteosarcoma]]."
 ==Also known as==